Citi finds biotech executives jump ship ahead of bad drug trials

Biotech stocks reversed course and ended lower in the week ended March 26, drawing inspiration from the broad.....»»

The Energy and Commerce Committee panel began hearing testimony from the five companie.....»»

Biotech stocks advanced in the week ended Jan. 15, defying the softness experienced by the broader market. Pre-announcements continued to pour in, with most companies suggesting better-than-forecast revenues. read more.....»»

Aronora has secured $25 million in grants but is seeking a partner to take its drug candidates into Phase 3 clinical trials......»»

Gilead Sciences shares surged Friday morning following a media report detailing encouraging partial data from trials of the biotech company's experimental drug remdesivir in severe COVID-19 patients. Fred Katayama reports......»»

Aiming to accelerate treatments against COVID-19 into mid-stage clinical trials in three to five months, Vir Biotechnology Inc. said Monday that it signed a collaboration with drug giant GlaxoSmithKline that includes a $250 million equity stake in t.....»»

Vir Biotechnology Inc. teamed with WuXi Biologics and Biogen Inc. to rush a potential treatment for COVID-19 patients into clinical trials, possibly as soon as June. San Francisco-based Vir (NASDAQ: VIR) said early Wednesday that its potential ant.....»»

The Houston company's drug candidate has shown promising results in combatting MERS and SARS in mice in pre-clinical trials......»»

The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either. read more.....»»

The biopharma spac.....»»

President Donald Trump said Monday he’s asked pharmaceutical companies to speed up work on a coronavirus vaccine, ahead of an afternoon meeting with drug-company executives......»»

Industry executives claim the proposed law will inhibit the development of life-saving medicationsRelated Stocks: ABBV, GILD, XNCR, MRK, LLY,.....»»

Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies......»»

Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. read more.....»»

Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. read more.....»»

Shares of Mallinckrodt PLC were rocked Thursday, putting them on track for a record low close, after a report that the specialty drug company had hired restructuring advisers and was considering bankruptcy ahead of federal opioid trials......»»

Shares of Mallinckrodt PLC were suffering their biggest-ever one-day selloff toward a record low Thursday, after a report that the specialty drug company had hired restructuring advisers and was considering bankruptcy ahead of federal opioid trials......»»

The biotech space saw muted activity in the week ended Aug. 30. Among the notable news of the week: Amgen, Inc. (NASDAQ: AMGN)'s $13.4-billion deal to buy the psoriasis drug Otezla from Celgene Corporation (NAS.....»»

Oklahoma's $572 million judgment against Johnson & Johnson will likely be followed by more trials and legal settlements seeking to hold a drug company accountable for a U.S. opioid crisis that has ripped apart lives and communities. .....»»

Oklahoma's $572 million judgment against Johnson & Johnson will likely be followed by more trials and legal settlements seeking to hold a drug company accountable for a U.S. opioid crisis that has ripped apart lives and communities. .....»»